Skip to Content
August, 8 2023

Transforming Cell Manufacturing  

Cellares to Revolutionize Cell Therapy Manufacturing with SteraMist iHP Technology Implemented

In a groundbreaking move poised to reshape the landscape of cell therapy manufacturing, TOMI has joined forces with Cellares, a pioneer in automated cell therapy manufacturing solutions. The collaboration is set to integrate SteraMist ionized Hydrogen Peroxide (iHP) technology into Cellares’ innovative Cell Shuttle—a cutting-edge solution designed to streamline and enhance cell therapy production. 

A Glimpse into the Partnership 

On August 3rd, 2023, TOMI announced an exciting collaboration with Cellares. This strategic partnership seeks to incorporate SteraMist iHP technology into Cellares’ revolutionary Cell Shuttle—an automated system that promises to redefine the way cell therapies are manufactured. 

The Cell Shuttle, created and developed by Cellares, is a game-changing leap forward in the field of cell therapy manufacturing. This innovative system offers an end-to-end automated approach, minimizing inefficiencies and maximizing productivity. One of its standout features is its capacity to simultaneously produce cell therapies for up to 16 different patients, a monumental improvement compared to traditional manufacturing methods. 

The Role of SteraMist iHP Technology

Recognizing the critical significance of maintaining a sterile environment within the confined spaces of the Cell Shuttle, Cellares turned to SteraMist iHP technology. This decontamination technology offers a comprehensive and effective solution. Its microscopic particles provide a unique advantage in terms of efficacy and safety when compared to other available decontamination methods on the market. 

A Partnership of Innovation and Expertise

The partnership between TOMI and Cellares dates back to 2021, and after intensive collaboration, they are now in the final stages of developing SteraMist iHP-equipped prototypes for the Cell Shuttle. TOMI’s team has meticulously designed a sleek, compliant, and efficient system that seamlessly integrates with Cellares’ groundbreaking technology. These systems are not only compact but also uphold high industry standards. 

Daniele Malleo, PhD, VP of Research & Development at Cellares, expressed their confidence in the combined efforts of both companies. “Our collaboration with TOMI and SteraMist iHP technology has been instrumental in bringing effective decontamination to the Cell Shuttle,” Malleo stated. They firmly believe that their innovative design, coupled with SteraMist iHP decontamination, will set new benchmarks in the cell therapy manufacturing sector. 

E.J. Shane, TOMI’s COO, conveyed their excitement about the collaboration, emphasizing the tailor-made approach they have taken. “We continue to seek out and build strong partnerships with leading life science manufacturers where there is a need for all the advantages of SteraMist iHP disinfection technology,” Shane mentioned. The collaboration not only underscores the commitment to innovation but also highlights the shared vision to drive excellence within the life sciences industry. 

In the realm of cell therapy manufacturing, the TOMI-Cellares collaboration stands as a testament to the transformative power of partnership. As SteraMist iHP technology seamlessly integrates into the Cell Shuttle, the potential for a more efficient and productive cell therapy production becomes a promising reality on the horizon. This collaboration serves as a beacon of innovation and progress, inspiring others in the industry to push boundaries and explore new frontiers in science and technology.